Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

American Journal of Ophthalmology

Volumn 132, Issue 4, 2001, Pages 472-484

  Netland, Peter A ^a   Landry, Theresa ^b   Sullivan, E Kenneth ^b   Andrew, Russell ^b   Silver, Lewis ^b   Weiner, Alan ^b   Mallick, Sushanta ^b   Dickerson, Jaime ^b   Bergamini, M V W ^b   Robertson, S M ^b   Davis, Alberta A ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; PROSTAGLANDIN F; TIMOLOL; TRAVOPROST;

ARTICLE; BLEPHARITIS; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ETHNIC GROUP; EYE INJURY; FEMALE; HEADACHE; HUMAN; HYPEREMIA; HYPERTENSION; INFECTION; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; IRIS DISEASE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; VISUAL DISORDER; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DOUBLE-BLIND METHOD; EYE COLOR; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; IRIS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PIGMENTATION DISORDERS; PRODRUGS; PROSTAGLANDINS F, SYNTHETIC; SAFETY; TIMOLOL; TREATMENT OUTCOME;

EID: 0034810344     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)01177-1     Document Type: Article

References (16)

1. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eiconoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha- 1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res 1987;44:217-226.
2. Hejkal TW, Toris CB, Camras CB. Prostaglandin analogs. In: Netland PA, Allen RC (editors). Glaucoma Medical Therapy: Principles and Management. San Francisco: The American Academy of Ophthalmology, 1999, pp. 113-131.
3. Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 1999;51:685-694.
4. Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther 1999;15:323-336.
5. Hellberg MR, Sallee V, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocular Pharm Ther. Forthcoming.
6. Garadi R, Silver L, Landry T, Turner FD. Travoprost: a new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure. Invest Ophthalmol Vis Sci 1999;40:S831.
7. The European Agency for the Evaluation of Medicinal Products. ICH Topic E9, statistical principles for clinical trials. Document CPMP/ICH/363/96. September 1998.
8. The European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority. Document CPMP/EWP/482/99. July 2000.
9. Westfall P, Tobias R, Rom D, Wolfinger R, Hochberg Y. Multiple comparisons and multiple tests using the SAS System. Cary, NC: SAS Institute, 1999:35-37.
10. Patel SS, Spencer CM. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996;9:363-378.
11. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 1991;325:1412-1417.
12. Hiller R, Kahn HA. Blindness from glaucoma. Am J Ophthalmol 1975;80:62-69.
13. Wilson R, Richardson TM, Hertzmark, E, Grant WM. Race as a risk factor for progressive glaucomatous damage. Ann Ophthalmol 1985;17:653-659.
14. Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol 1985;99:383-387.
15. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of open-angle glaucoma. The Baltimore Eye Study. JAMA 1991;266:369-374.
16. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998;105:1146-1164.